Inflammatory and hemostatic biomarkers associated with early recurrent ischemic lesions in acute ischemic stroke

Stroke

Volumn 40, Issue 5, 2009, Pages 1653-1658

  Kang, Dong Wha ^a   Yoo, Sung Hee ^a   Chun, Sail ^a   Kwon, Kyum Yil ^a   Kwon, Sun U ^a   Koh, Jae Young ^a   Kim, Jong S ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Acute ischemic stroke; D dimer; Diffusion weighted imaging; Recurrence

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; D DIMER; FIBRINOGEN; HEMOSTATIC AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; FIBRINOLYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE DISEASE; AGED; ANTICOAGULATION; ARTICLE; ATHEROSCLEROSIS; BLOOD CLOT LYSIS; BLOOD CLOTTING; BRAIN INFARCTION; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; DISEASE COURSE; ENCEPHALITIS; FEMALE; HOSPITAL ADMISSION; HUMAN; INFORMATION PROCESSING; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RECANALIZATION; RECURRENT DISEASE; RISK FACTOR; BLOOD; CLASSIFICATION; HEMOSTASIS; IMAGE PROCESSING; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY; REGRESSION ANALYSIS; STATISTICAL ANALYSIS; STROKE;

ACUTE DISEASE; AGED; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; DATA INTERPRETATION, STATISTICAL; DIFFUSION MAGNETIC RESONANCE IMAGING; DISEASE PROGRESSION; ENCEPHALITIS; FEMALE; FIBRINOLYTIC AGENTS; HEMOSTASIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; REGRESSION ANALYSIS; RISK FACTORS; STROKE;

EID: 65549093529     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.108.539429     Document Type: Article

References (29)

1. Sacco RL, Foulkes MA, Mohr JP, Wolf PA, Hier DB, Price TR. Determinants of early recurrence of cerebral infarction. The Stroke Data Bank. Stroke. 1989;20:983-989.
2. Sacco RL, Shi T, Zamanillo MC, Kargman DE. Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: the Northern Manhattan Stroke Study. Neurology. 1994;44: 626-634.
3. Kang DW, Latour LL, Chalela JA, Dambrosia J, Warach S. Early ische-mic lesion recurrence within a week after acute ischemic stroke. Ann Neurol. 2003;54:66-74.
4. Coutts SB, Hill MD, Simon JE, Sohn CH, Scott JN, Demchuk AM. Silent ischemia in minor stroke and TIA patients identified on MR imaging. Neurology. 2005;65:513-517.
5. Kang DW, Latour LL, Chalela JA, Dambrosia JA, Warach S. Early and late recurrence of ischemic lesion on MRI: evidence for a prolonged stroke-prone state? Neurology. 2004;63:2261-2265.
6. Kang DW, Lattimore SU, Latour LL, Warach S. Silent ischemic lesion recurrence on magnetic resonance imaging predicts subsequent clinical vascular events. Arch Neurol. 2006;63:1730-1733.
7. Sylaja PN, Coutts SB, Subramaniam S, Hill MD, Eliasziw M, Demchuk AM. Acute ischemic lesions of varying ages predict risk of ischemic events in stroke/TIA patients. Neurology. 2007;68:415-419.
8. Cho AH, Kim JS, Jeon SB, Kwon SU, Lee DH, Kang DW. Mechanism of multiple infarcts in multiple cerebral circulations on diffusion-weighted imaging. J Neurol. 2007;254:924-930.
9. Roh JK, Kang DW, Lee SH, Yoon BW, Chang KH. Significance of acute multiple brain infarction on diffusion-weighted imaging. Stroke. 2000; 31:688-694.
10. Coull AJ, Rothwell PM. Underestimation of the early risk of recurrent stroke: evidence of the need for a standard definition. Stroke. 2004;35: 1925-1929.
11. Ay H, Furie KL, Singhal A, Smith WS, Sorensen AG, Koroshetz WJ. An evidence-based causative classification system for acute ischemic stroke. Ann Neurol. 2005;58:688-697.
12. Cho KH, Kim JS, Kwon SU, Cho AH, Kang DW. Significance of susceptibility vessel sign on T2ß-weighted gradient echo imaging for identification of stroke subtypes. Stroke. 2005;36:2379-2383.
13. Gaffney PJ, Brasher M. Subunit structure of the plasmin-induced degradation products of crosslinked fibrin. Biochim Biophys Acta. 1973;295: 308-313.
14. Lowe GD, Rumley A. Use of fibrinogen and fibrin D-dimer in prediction of arterial thrombotic events. Thromb Haemost. 1999;82:667-672.
15. Lip GY, Lowe GD. Fibrin D-dimer: a useful clinical marker of thrombo-genesis? Clin Sci (Lond). 1995;89:205-214.
16. Cushman M, Folsom AR, Wang L, Aleksic N, Rosamond WD, Tracy RP, Heckbert SR. Fibrin fragment D-dimer and the risk of future venous thrombosis. Blood. 2003;101:1243-1248.
17. Eichinger S, Minar E, Bialonczyk C, Hirschl M, Quehenberger P, Schneider B, Weltermann A, Wagner O, Kyrle PA. D-dimer levels and risk of recurrent venous thromboembolism. JAMA. 2003;290:1071-1074.
18. Lowe GD, Yarnell JW, Rumley A, Bainton D, Sweetnam PM. C-reactive protein, fibrin D-dimer, and incident ischemic heart disease in the Speedwell study: are inflammation and fibrin turnover linked in patho-genesis? Arterioscler Thromb Vasc Biol. 2001;21:603-610.
19. Folsom AR, Aleksic N, Park E, Salomaa V, Juneja H, Wu KK. Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol. 2001;21:611-617.
20. Moss AJ, Goldstein RE, Marder VJ, Sparks CE, Oakes D, Greenberg H, Weiss HJ, Zareba W, Brown MW, Liang CS, Lichstein E, Little WC, Gillespie JA, Van Voorhees L, Krone RJ, Bodenheimer MM, Hochman J, Dwyer EM Jr, Arora R, Marcus FI, Watelet LF, Case RB. Thrombogenic factors and recurrent coronary events. Circulation. 1999;99:2517-2522.
21. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Rumley A, Lowe GD. Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation. 2001;103:2323-2327.
22. Barber M, Langhorne P, Rumley A, Lowe GD, Stott DJ. Hemostatic function and progressing ischemic stroke: D-dimer predicts early clinical progression. Stroke. 2004;35:1421-1425.
23. Barber M, Langhorne P, Rumley A, Lowe GD, Stott DJ. D-dimer predicts early clinical progression in ischemic stroke: confirmation using routine clinical assays. Stroke. 2006;37:1113-1115.
24. Delgado P, Alvarez-Sabin J, Abilleira S, Santamarina E, Purroy F, Arenillas JF, Molina CA, Fernandez-Cadenas I, Rosell A, Montaner J. Plasma D-dimer predicts poor outcome after acute intracerebral hemorrhage. Neurology. 2006;67:94-98.
25. Juvela S, Siironen J. D-dimer as an independent predictor for poor outcome after aneurysmal subarachnoid hemorrhage. Stroke. 2006;37:1451-1456.
26. Robson SC, Shephard EG, Kirsch RE. Fibrin degradation product D-dimer induces the synthesis and release of biologically active IL-1 beta, IL-6 and plasminogen activator inhibitors from monocytes in vitro. Br J Haematol. 1994;86:322-326.
27. The International Stroke Trial (1ST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet. 1997;349:1569-1581.
28. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. JAMA. 1998;279: 1265-1272.
29. Berge E, Abdelnoor M, Nakstad PH, Sandset PM. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. Lancet. 2000;355: 1205-1210.